00857nam0-22003011i-450-99000062608040332120001010000062608FED01000062608(Aleph)000062608FED0100006260820001010d--------km-y0itay50------baitay-------001yyMATHTENSORA system for doing tensor analysis by computerPARKER L. - CHRISTENSEN S.M.USAAddison-Wesley1994Calcolo MatricialeCalcolatori elettronici e applicazioniProgrammazione Lineare.Parker,Leonard31716ITUNINARICAUNIMARCBK99000062608040332107 D-134 CNR4948DINSCDINSCMathTensor188451UNINAING0102345nam 2200529 a 450 991046158680332120170814163321.01-60805-297-4(CKB)2670000000148694(EBL)864207(OCoLC)779141401(SSID)ssj0000942934(PQKBManifestationID)11492225(PQKBTitleCode)TC0000942934(PQKBWorkID)10976890(PQKB)11670260(OCoLC)785783102(MiAaPQ)EBC864207(EXLCZ)99267000000014869420120315d2012 uy 0engur|n|---|||||txtccrMultiple myeloma[electronic resource] a new era of treatment strategies /editors, Klaus Podar, Kenneth C. Anderson[U.S.A.] Bentham Science Publishers[2012]1 online resource (217 p.)Description based upon print version of record.1-60805-609-0 Includes bibliographical references and index.section 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies.Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cellMultiple myelomaTreatmentElectronic books.Multiple myelomaTreatment.616.99/418616.99418Podar Klaus876631Anderson Kenneth C876632MiAaPQMiAaPQMiAaPQBOOK9910461586803321Multiple myeloma1957490UNINA